 |
5 Diseases |  |
9 Trials |
|
9 Trials |  |
228 News |  |
| «123456789101112» |
- || Columvi (glofitamab) / Roche, Lunsumio (mosunetuzumab) / Roche, Biogen
Failed mosunetuzumab, could potentially access glofitamab (Twitter) - May 8, 2023
- Lunsumio (mosunetuzumab) / Roche, Biogen
Response-adapted mosunetuzumab for untreated follicular and marginal zone lymphomas: significant monotherapy activity seen in results of an interim efficacy analysis () - May 4, 2023 - Abstract #ICML2023ICML_713;
- Lunsumio (mosunetuzumab) / Roche, Biogen, Yescarta (axicabtagene ciloleucel) / Gilead
Matching-adjusted indirect comparison of axicabtagene ciloleucel vs mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments () - May 4, 2023 - Abstract #ICML2023ICML_667;
- Lunsumio (mosunetuzumab) / Roche, Biogen
Outpatient administration of mosunetuzumab in US community practice settings: perspectives and learnings from the Phase II MorningSun study () - May 4, 2023 - Abstract #ICML2023ICML_559;
- T-cell engaging bispecific antibodies in the management of relapsed/refractory follicular lymphoma (Room B2) - May 4, 2023 - Abstract #ICML2023ICML_361;
The prognostic value of PET and its role in response-adapted therapy will be presented and discussed. The impact of emerging T-cell engaging therapies on the FL treatment landscape will be explored along with factors influencing their use and adoption in clinical practice.
- Lunsumio (mosunetuzumab) / Roche, Biogen
Mosunetuzumab demonstrates durable responses in patients with relapsed/refractory follicular lymphoma and ?2 prior therapies: updated analysis of a pivotal Phase II study (Room A) - May 4, 2023 - Abstract #ICML2023ICML_271;
- Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
SUNMO: Phase III trial of mosunetuzumab plus polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in relapsed/refractory aggressive non-Hodgkin lymphoma (Cinema Corso) - May 4, 2023 - Abstract #ICML2023ICML_72;
- Lunsumio (mosunetuzumab) / Roche, Biogen
A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). (On Demand | Hall A; Poster Bd # 134a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3992;
P2
Correlative studies aim at determining predictive biomarkers of response, including immune signatures and dynamics of circulating tumor DNA during study therapy. Clinical trial information: NCT04792502.
- Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab) / Roche, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. (On Demand | Hall A; Poster Bd # 133a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3990;
P3
Enrollment is ongoing, and an estimated 75 sites globally will enroll approximately 222 pts (M-Pola, 148 pts; R-GemOx, 74 pts). Clinical trial information: NCT05171647.
- Zynlonta (loncastuximab tesirine) / Overland ADCT BioPharma, Mitsubishi Tanabe, SOBI
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7). (On Demand | Hall A; Poster Bd # 130b) - Apr 26, 2023 - Abstract #ASCO2023ASCO_3985;
P1b
In preclinical models, Lonca + polatuzumab vedotin (Pola) showed improved efficacy...Planned arms include Lonca + Pola (arm C), glofitamab (arm E), or mosunetuzumab (arm F)...The study opened in December 2021; 12 pts have been enrolled and 9 treated in the Lonca + Pola arm. Clinical trial information: NCT04970901.
- ||| Here are the 8 RCTs (sorry some Ph2 not Ph3): Loncastuximab NCT04974996 ME-401 NCT04517435 Acalabrutinib NCT04529772 Acalabrutinib NCT04546620 Tafasitamab+ len NCT04824092 Mosunetuzumab NCT03677141 Glofitamab NCT04914741 Epcoritamab NCT0557897 (Twitter) - Apr 25, 2023
P1/2, P1b,
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
Monotherapy: Hopefully we will soon see what mosunetuzumab monotherapy / combos offer in high-tumor burden FL. (Twitter) - Apr 18, 2023
- ||| Lunsumio (mosunetuzumab) / Roche, Biogen
Very excited to see the mosunetuzumab DLBCL data in print! Part of the motivation for our IIT of mosun + salvage pre-ASCT. https://t.co/F11biEHmcY (Twitter) - Apr 17, 2023
- ||| Lunsumio (mosunetuzumab) / Roche, Biogen
Mosunetuzumab in r/r DLBCL 88pts (DLBCL 74%, tFL 26%) CR 24%, ORR 42%, medianTTR 1.4mo, mDOR 7mo, medianTT CR 3mo mPFS 3.2mo, mOS 11.5mo Prior CAR-T: 26/88 w CR 12% CRS 26% (mainly Gr 1-2) Small n w bulky dx...#lymsm Kudos to @nancybartlettMD & team https://t.co/FnO96QnxyI (Twitter) - Apr 17, 2023
- || Lunsumio (mosunetuzumab) / Roche, Biogen
Off label mosunetuzumab if possible (approved in 3L FL), very low CRS, if not, tafa + len (Twitter) - Apr 13, 2023
- Lunsumio (mosunetuzumab) / Roche, Biogen
LUNSUMIO (mosunetuzumab-axgb): A Novel, First-in-class, T-cell Engaging Bispecific Antibody in 3L+ Follicular Lymphoma (Theater 1) - Apr 10, 2023 - Abstract #ASCO2023ASCO_742;
Join us for a clinical presentation that introduces the first bispecific antibody targeting both CD20 on B cells and CD3 on T cells. Learn about the proposed mechanism of action and its potential impact on patients with FL who have received ?2 lines of systemic therapy.
- ||| Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Enrollment closed: GO40516: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 30, 2023
P1/2, N=422, Active, not recruiting, Sponsor: Hoffmann-La Roche
Learn about the proposed mechanism of action and its potential impact on patients with FL who have received ?2 lines of systemic therapy. Recruiting --> Active, not recruiting
- |||| Enrollment open, CAR T-Cell Therapy: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov) - Mar 15, 2023
P2, N=396, Recruiting, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Blincyto (blinatumomab) / Astellas, Amgen, Lunsumio (mosunetuzumab) / Roche, Biogen
EVOLVETM: A novel T cell engager platform with integrated CD2 costimulation engineered for the treatment of immune suppressive tumors (Section 24; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_5132;
Not yet recruiting --> Recruiting Bispecific antibodies which bind a tumor antigen and the CD3 heterodimer of the T cell receptor to form a synthetic immunological synapse represent a class of T cell engagers that has been clinically validated with the approvals of blinatumomab (Blinctyo
- Lunsumio (mosunetuzumab) / Roche, Biogen
Preclinical evaluation of mosunetuzumab for the treatment of relapsed/refractory chronic lymphocytic leukemia (Section 25; Poster Board #8) - Mar 14, 2023 - Abstract #AACR2023AACR_4015;
Although single-agent Mosun treatment can activate T-cells in CLL patient samples and result in B-cell death, the response is suboptimal due to a number of factors, including deficient T cell activation and high B/T ratio. Ongoing work is focusing on evaluating drug partners to debulk CLL B cells or prime CLL T cells for better B-cell killing by Mosun.
- | Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 13, 2023
P1, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Ongoing work is focusing on evaluating drug partners to debulk CLL B cells or prime CLL T cells for better B-cell killing by Mosun. Trial completion date: Jul 2023 --> Sep 2024 | Trial primary completion date: Jul 2023 --> Sep 2024
- || Venclexta (venetoclax) / Roche, AbbVie, Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Mar 13, 2023
P1, N=56, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jul 2023 --> Sep 2024 | Trial primary completion date: Jul 2023 --> Sep 2024 Trial completion date: Oct 2025 --> Jul 2027 | Trial primary completion date: Dec 2023 --> Feb 2026
- || Lunsumio (mosunetuzumab) / Roche, Biogen
mosunetuzumab (Twitter) - Mar 9, 2023
- Lunsumio (mosunetuzumab) / Roche, Biogen
A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Third- or Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_2034;
P1/2
A three-state (progression-free, progression, death) partitioned-survival model was developed to simulate the lifetime costs and outcomes of Mosun against 7 comparators: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), tazemetostat (taz, EZH2 wild-type only), rituximab in combination with lenalidomide (R-Len) or bendamustine (R-Benda), obinutuzumab in combination with bendamustine (O-Benda), and 3L+ FL treatments used in routine care by a retrospective real-world cohort (RW). Mosun is projected to be cost-effective compared with most approved regimens for the treatment of adults with 3L+ R/R FL.
- Lunsumio (mosunetuzumab) / Roche, Biogen
A Budget Impact Analysis of the Introduction of Mosunetuzumab for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US) () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_993;
Mosun is projected to be cost-effective compared with most approved regimens for the treatment of adults with 3L+ R/R FL. Comparators were: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), tazemetostat (taz), rituximab + lenalidomide (R-Len), copanlisib (copan), and older therapies (rituximab or obinutuzumab
- ||| Lunsumio (mosunetuzumab) / Roche, Biogen, Zynlonta (loncastuximab tesirine) / Overland ADCT BioPharma, Mitsubishi Tanabe, SOBI, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Clinical: Probably mosunetuzumab outside a study. We are observing promising efficacy in this population with loncastuximab & rituximab. Hope to present preliminary analysis at #ASH2023 https://t.co/lBKZpOycZZ (Twitter) - Mar 8, 2023
- | Lunsumio (mosunetuzumab) / Roche, Biogen
Journal: Mosunetuzumab (Lunsumio) for follicular lymphoma. (Pubmed Central) - Mar 7, 2023
Comparators were: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), tazemetostat (taz), rituximab + lenalidomide (R-Len), copanlisib (copan), and older therapies (rituximab or obinutuzumab No abstract available
- || Lunsumio (mosunetuzumab) / Roche, Biogen
🔴 Swissmedic homologue l'anticancéreux Lunsumio du laboratoire @Roche. L'anticorps sert au traitement du lymphome folliculaire récidivant ou réfractaire. https://t.co/vP8pSIIjJO (Twitter) - Mar 6, 2023
- || Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date: GO40516: A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 6, 2023
P1/2, N=422, Recruiting, Sponsor: Hoffmann-La Roche
No abstract available Trial completion date: Nov 2023 --> Jul 2025
- Lunsumio (mosunetuzumab) / Roche, Biogen
LUNSUMIO (mosunetuzumab-axgb): A Novel, First-in-class, T-cell Engaging Bispecific Antibody in 3L+ Follicular Lymphoma (Hyatt Texas Ballroom DEF) - Feb 23, 2023 - Abstract #ONS2023ONS_206;
Join us for a clinical presentation that introduces the first bispecific antibody targeting both CD20 on B cells and CD3 on T cells. Learn about the proposed mechanism of action and its potential impact on patients with FL who have received ?2 prior therapies.
- ||| Lunsumio (mosunetuzumab-axgb) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed: GO29781: A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 17, 2023
P1/2, N=836, Active, not recruiting, Sponsor: Genentech, Inc.
Learn about the proposed mechanism of action and its potential impact on patients with FL who have received ?2 prior therapies. Recruiting --> Active, not recruiting
- || Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date, Monotherapy: MorningSun: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (clinicaltrials.gov) - Feb 13, 2023
P2, N=345, Recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Dec 2026 --> Jul 2028
- | Lunsumio (mosunetuzumab-axgb) / Roche
Phase classification: CO41942: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma (clinicaltrials.gov) - Feb 8, 2023
P1, N=169, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Dec 2026 --> Jul 2028 Phase classification: P1/2 --> P1
- |||| lenalidomide / Generic mfg., Lunsumio (mosunetuzumab) / Roche, Biogen
Mosunetuzumab + Lenalidomide in R/R Follicular Lymphoma #lymsm (Twitter) - Feb 7, 2023
- ||||| Lunsumio (mosunetuzumab) / Roche, Biogen
Monotherapy: Mosunetuzumab Monotherapy in R/R Follicular Lymphoma : Duration of CR and PFS With Mosunetuzumab vs Last Prior Therapy #lymsm (Twitter) - Feb 7, 2023
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
P1 data: Mosunetuzumab phase 1 currently enrolling for CLL. Maybe see something at next ASH? (Twitter) - Feb 7, 2023
- || Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Enrollment closed, Monotherapy: GO40554: Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Jan 31, 2023
P1/2, N=188, Active, not recruiting, Sponsor: Hoffmann-La Roche
Phase classification: P1/2 --> P1 Recruiting --> Active, not recruiting
- ||| Lunsumio (mosunetuzumab) / Roche, Biogen
Also mosunetuzumab for R/R follicular lymphoma ☝️. (Twitter) - Jan 28, 2023
- || Lunsumio (mosunetuzumab-axgb) / Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 27, 2023
P1/2, N=118, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Jun 2023 | Trial primary completion date: Sep 2025 --> Jun 2023
- || Lunsumio (mosunetuzumab) / Roche, Biogen
#ASH22 | Quali vantaggi dall'impiego di #mosunetuzumab nel trattamento del #linfomafollicolare? @StefanoLuminari incontrato a New Orleans. @UNIMORE_univ https://t.co/kEWfuyYmyb (Twitter) - Jan 24, 2023
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
FDA event: The FDA approved #Lunsumio for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. https://t.co/oNSCQdYWNS @elizabeth_budde #FDA #lymphoma (Twitter) - Jan 22, 2023
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
An expert from Rutgers Cancer Institute discusses ongoing research for mosunetuzumab in relapsed/refractory follicular lymphoma, as well as the importance of deploying the agent in the community setting. #lymsm | @DrMatasar @RutgersCancer https://t.co/hQvICafcP4 (Twitter) - Jan 20, 2023
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
FDA event: The FDA approved #Lunsumio for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. https://t.co/oNSCQdYWNS @elizabeth_budde #FDA #lymphoma (Twitter) - Jan 18, 2023
- |||||| Lunsumio (mosunetuzumab) / Roche, Biogen
CAR T-Cell Therapy: An expert from Rutgers Cancer Institute indicates that mosunetuzumab may limit unmet needs commonly associated with CAR T-cell therapy such as cost, tolerability, and access. #lymsm | @DrMatasar @RutgersCancer https://t.co/juenX58Oby (Twitter) - Jan 18, 2023
- ||| Lunsumio (mosunetuzumab) / Roche, Biogen
Happy to have had the opportunity to share my thoughts on mosunetuzumab with @cancernetwork (Twitter) - Jan 17, 2023
- |||||| Lunsumio (mosunetuzumab) / Roche, Biogen
Clinical: An expert from Rutgers Cancer Institute reviews data that lead to the approval of mosunetuzumab for patients with relapsed/refractory follicular lymphoma. #lymsm | @DrMatasar @RutgersCancer https://t.co/MAa7YmwREy (Twitter) - Jan 17, 2023
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
FDA event: The FDA approved #Lunsumio for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. https://t.co/oNSCQdYWNS @elizabeth_budde #FDA #lymphoma (Twitter) - Jan 14, 2023
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
Mosunetuzumab Shows High Response Rates in Relapsed/Refractory Follicular Lymphoma #lymsm #oncology #nursing #ASH22 @nancybartlettMD @SitemanCenter Link: https://t.co/9U9Uipw3gk (Twitter) - Jan 11, 2023
- |||| Lunsumio (mosunetuzumab) / Roche, Biogen
FDA event: The FDA approved #Lunsumio for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. https://t.co/oNSCQdYWNS @elizabeth_budde #FDA #lymphoma (Twitter) - Jan 10, 2023
- ||||| Lunsumio (mosunetuzumab) / Roche, Biogen
Clinical: Great summary of mosunetuzumab (bsAb in #lymsm) by @Rcl14L. I’d def been surprised when I heard it didn’t require a REMS, unlike blina #leusm or tec #MMsm. Looks like this slide is why! Plus, hospitalization was never mandated on protocol to begin with. (Twitter) - Jan 7, 2023